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1073-170 Improved In-Hospita l  Outcomes After Percutaneous  
Coronary Intervention in the Era of Routine 
Glycoprotein l ib/I l ia Inh ib i t ion  and Stant ing  
Cynthia A. Jackevicius. Karen Mackie, Peter Seidelin, Steve Minor, Paul Daly, Alan 
Barolet, Leonard Schwartz, Peter McLaughlin, Doug Ing, John Ross, Vlad Dzavik, 
University Health Network, Toronto, Ontario, Canada. 
Background: Clinical trials have shown that stenting improves clinical outcomes in 
patients undergoing percutaneous coronary intervention (PCI). More recently, clinical tri- 
als have demonstrated the benefit of Glycoprotein lib/Ilia Inhibitor (GPI) therapy in the 
setting of PCI in further reducing adverse cardiac outcomes. Using a PCI database at a 
large tertiary care institution, our objectives were to conduct a practice pattern analysis to 
assess a selected vs routine strategy of GPI and stant use in the prevention of adverse 
cardiac outcomes post-PCI. 
Methods: All patients who underwent PCI at the institution from March 1994 to March 
2001 were part of the cohort. Patients were divided into 3 cohorts: pre-GPI + selected 
stant use, selected GPI + routine stant usa, and routine GPI + stent use. A multivariate 
logistic regression model was constructed using 3 time variables to represent the differ- 
ent strategy periods, with the rate of in-hospital myocardial infarction, death or abrupt clo- 
sure as the primary composite andpoint. The models were adjusted for age, gender, 
diabetes, case urgency and lesion type. 
Results: The cohort consisted of 9,739 patients, 3,476, 4,429, and 1,832 in periods (P) 
1,2, and 3 respectively. 73% of the cohort were male and the mean age (+/-sd) was 
60.9+/-11.4 years. Stent use increased from 33.5% in P1 to 80.6% in P2 and 90.8% in 
P3. GPI use increased from 0% in P1 to 16.4% in P2 and 90.5% in P3. There was a sig- 
nificant difference in the unadjusted composite endpoint between the three periods 
(4.34% vs 3.16% vs 2.51%, respectively for P1, P2, P3; p<0.001). In the multivariate 
regression analysis, the composite endpolnt was significantly greater in P1 and P2 as 
compared to P3 (OR [P1 vs P3] = 2.28, p<0.001; OR [P2 vs P3]=1.43, p=0.049). The rate 
of bleeding complications requiring medical therapy or prolonging hospital stay signifi- 
cantly decreased between PI and P3. 
Conclusions: A significant reduction in adverse cardiac outcomes was observed in asso- 
ciation with a strategy of routine use of GPI therapy and stanting in a large consecutive 
PCI cohort. This finding remained significant after adjusting for changes in potentially 
confounding patient characteristics between the periods assessed. 
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1098-164 Cost -E f fect iveness  of  C-React ive Protein Screening to  
Target Stat in Therapy 
Gavin J. Blake. Paul M. Ridker, Karen M. Kuntz, Brigham and Women's Hospital, Boston, 
Massachusetts, Harvard Schoo/ of Public Health, Boston, Massachusetts. 
Background: StaUn therapy has been shown to reduce coronary event rates among 
individuals with elevated C-reactive protein (CRP) levels but without overt hypedipi- 
demia. 
Methods: We used a Markov model to estimate the incremental cost-effectiveness of 
CRP screening followed by targeted statin therapy for elevated CRP levels compared to 
diet alone for the primary prevention of myocardial infarction (MI) and stroke among indi- 
viduals without overt hyperlipidemia. A societal perspective was used. 
Results: The incremental cost-effectiveness ratio for the CRP screening strategy fol- 
lowed by targeted statin therapy compared with diet alone was $39.500/quality-adjusted 
life year (QALY) for 58-year-old men and $61.200/QALY for 58-year-old women. CRP 
screening was most cost-effective for 75-year-old men ($31,900/QALY) and least cost- 
effective for 35-year-old women ($134,200/QALY). Our results were most sensitive to the 
relative risk of MI, the cost of statin therapy, and the efficacy of statin therapy for prevent- 
ing MI in individuals with high CRP levels. If a higher risk population is considered, or the 
cost of statin therapy is reduced, the cost-effectiveness ratios of CRP screening improve 
significantly, and in some circumstances may be cost-saving. 
Conclusion: CRP screening to target statin therapy for the primary prevention of cardio- 
vascular disease among individuals without overt hypedipidemia may be relatively cost- 
effective for middle-aged men and high-risk middle-aged women. 
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1098-163 Cardiovascular Features and Prognosis of Middle-Aged 
and Elderly Adults With Renal Dysfunction: The Strong 
Heart Study 
Jonathan N. BeUa, Jennifer E. Liu, Mary J. Roman, David C. Robbins, Thomas K. Welt,/, 
Jay Sosenko, Andrew Narva, Philip Zager, Richard R. Fabsifz, Elisa T. Lee, Barbara V. 
Howard, Richard B. Devereux, The New York Presbyterian Hospita/-WeN Medica/ 
Co/lege of Come//Universi~ New York, New York, Bronx-Lebanon Hospita/ Center- 
A/bert Einstein College of Medicine, Bronx, New York. 
Background: The spectrum of cardiac abnormalities and their impact on prognosis in 
adults with renal dysfunction have not been elucidated in population-based samples. 
Methods: Echocardiograms were analyzed in 2,907 American Indian participants in the 
second Strong Heart Study (SHS) examination who had normal renal function (NRF), 
332 with mild renal dysfunction (microalbuminuria or creatinine>l.8 mg/dl, [MRD]) and 
206 with moderate to severe renal dysfunction (macroalbuminuria or on dialysis, [SRD]). 
Results: There were no differences among subgroups in gender, age or body mass index 
(BMI). Compared to SHS participants with NRF, those with M or SRD had higher systolic 
(141±23 and 152±26 vs. 127±18 mmHg) and diastolic blood pressures (BP) (77±12 and 
77±12 vs. 75±10 mmHg, all p<0.001). There was a stepwise increase in heart rate in 
those with MRD (70±11) and SRD (73±10) from those with NRF (68±11 bpm, all 
p<0.001). Mean LV mass, adjusted for gender, age, BMI and systolic BP, was signifi- 
cantly higher in SHS participants with M or SRD (171 and 196 vs. 156 g, all p<0.001 ), as 
was mean relative wall thickness, adjusted for gender, age, BMI, systolic BP and heart 
rate (0.36 and 0.36 vs. 0.35, all p<0.05). Mean ejection fraction, adjusted for gender, age, 
BMI, SBP and LV mass, was lower in those with SRD compared to those with NRF or 
MRD (56 vs. 63 and 62% p<0.05), as was mean adjusted stress-corrected midwall short- 
ening (98 vs. 105 and 102%, p<0 01). SHS participants with M or SRD had lower mean F_J 
A, adjusted for gender, age. BMI, systolic BP and LV mass (0.85 and 0.80 vs. 0.91, 
p<0.001), indicating more impaired diastolic relaxation. The prevalences of LV wall 
motion abnormalities increased stepwise in SHS participants with NRF (7%) to MRD 
(15%) and SRD groups (32%, p<0.001). Incidences of all-cause death (14 and 29 vs. 
6%) and cardiovascular death (5 and 14 vs. 2%, all p<0.01) were higher in participants 
with MRD and SRD. Conclusion: In a population-based sample of middle-aged and aid* 
edy adults, abnormalities in left ventricular structure, systolic and diastolic function 
increased with severity of renal dysfunction, which may contribute to the high mortality 
associated with renal disease. 
1098-165 Clinical Trials Do Not Support Strong Association of 
Beta-Blocker Therapy With Fatigue, Depression, or 
Sexual Dysfunction 
Dennis T. Ko, Patricia R. Hebert, Christopher Coffey, Art Sedrakyan, Jeptha Curtis, 
Harlan M. Krumholz, Ya/e University School of Medicine, New Haven, Connecticut. 
Background: Beta-blocker (BB) therapy remains substantially underutilized in cardiac 
patients despite its proven mortality benefits. Reluctance to prescribe these agents and 
withdrawal of them may derive from concerns about their association with fatigue, 
depression and sexual dysfunction. 
Methods; We sought to review systematically the clinical trial evidence that BBs are 
associated with these adverse effects by performing a quantitative overview of random- 
ized placebo-controlled trials of BBs in myocardial infarction (MI), heart failure (HF) and 
hypertension (HTN). We used the general variance-basod method to combine results 
from individual trials and calculate unbiased estimates of the risks of fatigue, depression, 
and sexual dysfunction associated with BB therapy. 
Results: A total of 13 randomized placebo-controlled trials reported information about 
the adverse effects and studied BBs that are currently approved by the Food and Drug 
Administration for treatment of MI, HF or HTN. These trials included over 30,000 patients 
and followed patients from 6 to 59 mos. Patients assigned to long-term BB therapy expe- 
rienced small significant increases in the risks of fatigue (RR 1.09; 95% CI 1.05,1.14) and 
sexual dysfunction (RR 1.07; 95% CI 1.01,1.15), but not depression (RR 1.03; 95% CI 
0.96,1.11 ). There was a slight suggestion of heterogeneity among the trials, confined to a 
few older trials, all of which had higher relative risk estimates for the adverse effects than 
did the remaining trials. No heterogeneity was observed when the analysis was restricted 
to later generation BB trials. 
Conclusions: Long-term BB therapy is associated with very small increased risks of 
fatigue and sexual dysfunction, but not depression. Conventional wisdom that BB ther- 
apy is associated with substantial increases in the risks of these symptoms is not sub- 
stantiated by data from the clinical trials. 
1098-166 Speci f ic  Polymorphism Groups Within a PPARg-ABCA1 
Pathway Are Associated With Future Death or 
Myocardial In farct ion in Pat ients  With Angiogrephically 
Documented Coronary Artery Disease 
Corv A. Kina. Joseph B. Muhlestein, Noal I. Hart, Jill B. Faatz, Henri O. F. Mulhuizen, 
Jeffrey L. Anderson, Bryant M. Whiting, Benjamin D. Home, John F. Cadquist, LDS 
Hospifa/, Salt Lake City, Utah, University of Utah, Salt Lake Ci~ Utah. 
Background: Peroxisome proliferator-activatad receptor-y (PPAR-y) is a nuclear recep- 
tor that regulates lipid, glucose and insulin metabolism. It has been shown to have a reg- 
ulatory effect on cholesterol efflux through induction of the ATP-Binding Cassette 
Transporter I (ABCA1) gene. Because gone polymorphisms may be associated with ele- 
vated disease risk, we evaluated two common variants, one in the PPARy gene (C161T) 
and one in the ABCA1 gene (G596A), individually and in combination, for an association 
with future death or MI in patients with known coronary artery disease(CAD). 
Methods: DNA was extracted from peripheral blood obtained from 2,060 consenting 
patients undergoing coronary angiography who were enrolled into the catheterization 
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registry of the Intermountain Heart Collaborative Study and found to have significant 
CAD (_>70% in at least one major artery). Genofyping used PCR followed by restriction 
enzyme digestion and detection by ethidium bromide staining and gel electrophoresis. 
Patients were grouped according to their ABCA1 and PPAR7 genotypes and followed for 
clinical events for up to 5.8 years (mean, 2.2±1.5 years). 
Results: Average patient age was 65±11 years and 76% were male. ABCA1 genotype 
frequencies were 0.53, 0.39, and 0.08 for GG, AG, and AA, respectively, and for PPARy 
were 0.75, 0.23, and 0.02 for CC, CT, and 13, respectively; each was in Hardy-Weinberg 
equilibrium. In Cox regression, no ABCA1 nor PPARy allele predicted death/MI (all 
p=NS). The combination of the ABCA1 allele (homozygous or heterozygous) with 
homozygosify for the PPARy C allele carried a modest but significant risk of deeth/MI 
compared to the combined GG/CC genotype (univariate HR = 1.44, p=0.008; adjusted 
HR=1.35, p=0.03). No other ABCA1/PPARy combination increased risk for events. 
Concluaions: Individually, neither ABCA1 nor PPAR-y polymorphisms were significantly 
associated with risk for events; however, in combination, the PPARy (C161T) and 
ABCA1(G596A) variants significantly elevate risk for events. This observed synergy 
between two genes related to lipid metabolism requires confirmation and further study. 
1098-187 Coronary Plaque as a Replacement for Age in the 
Framingham Risk Equation 
Enrioue F. Schisterm~.rh Scott Grundy, Silvana Lawvere, Heidi Granser, John D. 
Fdedman, Daniel S. Berman, Cedars-Sinai Medical Center, Los Angeles, California. 
Background: The standard Framingham score (SFS) for predicting hard events is strongly 
weighted by age. The extent of coronary atherosclerosis increases with age, however there 
is large inter-individual variability in the rate of progression among those with disease. Elec- 
tron beam tomography (EBT) provides a method for assessing coronary plaque burden, 
thus offering the possibility of estimating a coronary age equivalent and using this modified 
age in place of chronological age. 
Methods: 5,686 consecutive patients who had EBT between Aug. 1998 and Dec. 2000 
were evaluated. CCS was calculated from EBT by the Agatston scoring technique, individ- 
ual modified age, based on the CCS, was calculated as the age at which an individuals cal- 
cium score was at the gender-matched 50th percentile based on previously published 
tables (Raggi et aL Circulation. 101(8):850-5). We incorporated the modified age in place of 
chronological age into the SFS creating a modified Framingham score (MFS). Three 10- 
year risk of hard events categories were calculated for the SFS and the MFS: 0-10 %, >10- 
20%, and >20%. Misclassification tables, means and Spearman correlations were com- 
puted. T-tests and Chi-square tests were used for mean and proportion comparisons, 
respectively. 
Results: As expected, age was significantly different by risk category in the SFS. However, 
no significant differences in age were observed in the three MFS risk categories. The corre- 
lation of SRS and MFS was 0.76 (p<0.001). Only, 1% of the SFS low risk group was reclas- 
sified as high risk by the MFS. 50% of the SFS intermediate patients were reclassified. Of 
those reclassified 18% became high risk and 32% were converted into the low risk MFS 
group. 33% of the high-nsk individuals based on SFS were reclassified to the lower dsk 
groups. Compared to SFS, the MFS classified 3 times as many patients as SFS in the 
high-risk category. Conclusion: Based on this method, we reclassified 48 % of the individu- 
als in intermediate and high-risk group. Our method of reclassification suggests that CCS 
in low risk SFS individuals does not change risk assessment. However, CCS has the 
potential to improve risk prediction for patients with intermediate or high SFS risk. 
1098-168 Inadequate Prediction of Death by the Framingham Risk 
Model for Patients With Existing, Angiographically- 
Defined Coronary Artery Disease 
Beniamin D. Home, Joseph B. Muhlestein, Chloe A. Allen Maycock, John F. Carlquist, 
Donald L. Lappe', Robed R. Pearson, Dale G. Renlund, Jeffrey L. Anderson, LDS 
Hospital, Salt Lake City, Utah, University of Utah, Salt Lake Ci~ Utah. 
Background: The Framingham Heart Study described risk factors fundamental to our 
current understanding of coronary artery disease (CAD) development. Although the 
Framingham Risk Model was built as a predictor of CAD onset (ROC area: 0.72 for 
women, 0.69 for men), current guidelines for prevention and treatment of future compli- 
cations (eg. mortality) among patients with existing CAD largely utilize that model. This 
study evaluated predictive risk models for CAD onset and for CAD mortality to determine 
differences in the predictive value of the Framingham risk factors for these two out- 
comes. 
Methods: A cohort of 4,238 patients was evaluated by coronary angiogrephy at the LDS 
Hospital, of which 3,098 (73%) had significant CAD (->1 lesion of >_70% stanosis) and 
1,097 (27%) had no CAD (all stenoses <10%). Of the 3,098 CAD patients, the first 2,585 
possessed 6-year mortality status of which 250 (9.7%) died. Demographic and cardiac 
risk factors were measured at the time of angiography; the design was cross-sectional for 
the CAD endpoint, but was prospective for mortality. 
Results: Predictive risk models were built using dsk scores based on regression [) val- 
ues. For CAD onset, logistic regression showed that age (dsk scores: <45 years [yr]= 0, 
45-49 yr = 2, 50-59 yr = 3, 60-64 yr = 5, 65-69 yr = 7, 70-74 yr = 8, >75 yr = 22), gender 
(male = 6), hypertension (yes = 1), hyperlipidemia (yes = 3), diabetes (yes = 2), and 
smoking (yes = 1) were significant predictors (all p<0.05). For CAD prediction, the ROC 
area was 0.746 with these risk scores. However, prediction of mortality by Cox regres- 
sion among patients with CAD at baseline showed that only age (<60 yr = 0, 60-64 yr = 2, 
65-69 yr = 3, 70-79 yr = 5, ->80 yr = 9) and diabetes (yes = 2) were predictors, while 
hyperlipidemia (yes = -1) was protective (ROC area for mortality risk scores: 0.689). 
Conclusions: The risk factors from the Framingham Risk Model, although predictive of 
CAD onset, are largely not predictive of long-term mortality among patients who have 
already developed CAD. Predictive mortality risk models that are built on population- 
based data from patients with existing CAD may provide better data for guiding therapy 
than does the use of risk models built to predict CAD onset. 
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1098-169 The Ef fect  o f  Passive Smoking on the Risk of  
Developing Acute Coronary Syndromes: The 
CARDIO2000 Study 
Demosthenes B. Panaoiotakos. Chdstos Pitsavos, Chdsfine Chrysohoou, John 
Skournas, Spyros Vellias, Christodoulos Stefanadis, Pavlos Toutouzas, University of 
Athens, Athens, Greece. 
BACKGROUND: Although the current smoking habit has been established as a major 
risk factor for developing coronary heart disease (CHD) several epidemiological studies 
have shown that the effect of passive smoking on the coronary risk is controversial. Aim 
of this study is to evaluate the role of passive smoking in the dsk of developing acute cor- 
onary syndromes (ACS). 
METHODS: Dudng 2000-01, we studied 848 male and female patients (32 to 76 years 
old) with first event of ACS and 1078 cardiovascular disease free controls, paired by sex 
and age. All the subjects were randomly selected from several Greek regions. Among 
several risk factors we evaluated, based on conditional logistic regression analysis, the 
effect of passive smoking (degree and duration) in the development of ACS. 
RESULTS: 317 (37%) of the patients and 242 (22%) of the controls were defined as non- 
smokers - passive smokers subjects. The analysis showed that non-smokers exposed to 
smoke had 20% higher coronary dsk (OR=1.20, 95% CI, 1.08-1.33, P<0.01) compared 
with non-smokers not exposed to smoke. Additionally, expose to husbands smoke 
increases by 78% the coronary risk in females (OR=1.78; 95 % CI 1.23 to 2.24, P- 
value<0.05). Also, passive smoking plays an additive role in the aetiology of ACS, since it 
was found to increase progressively the coronary risk in the presence of hypartension -
hypereholestarolemle - diabetes mellitus (P for trend<0.001). Finally, a significant ddse- 
response association was identified, showing that, approximately, 25 out of 125 non- 
smokers, who were exposed to the smoke up to one cigarette pack per day and 50 out of 
150 of those who were exposed to the smoke of more than one pack per day, will 
develop ACS, sometime in their life. 
CONCLUSIONS: Given the high prevalence of cigarette smoking among individuals in 
Mediterranean populations, the consequences of passive smoking to public health, 
regarding coronary heart disease, seems to be notable and becomes a major target for 
intervention. 
1098-170 Elevated Serum Creat in ine and Increased Morta l i ty  In 
Women and Elderly Heart Failure Patients 
Grace L. Smith, Martha J. Radford, Saif S. Rathore, Judith H. Lichtman, Suzanne G. 
Watnick, Harlan M Krumholz, Yale University School of Medicine, New Haven, 
Connecticut. 
Background: Elevated creatinine (Cr) in heart failure (HF) patients (pts) predicts 
increased mortality, but risks in specific patient subgroups are not clear. 
Methods: In 7,788 outpatients from the Digitalis Investigation Group trial, we examined 
how baseline Cr predicted 1 -year all-cause and HF death, after adjusting for body mass 
index, etiology, blood pressure, ejection fraction, New York Heart Association class, dia- 
betes, pulmonary edema, and medications. Models were stratified by sex and age (>=75, 
<75 years). Reported hazard ratios (HR) compare pts with Cr>=1.5 to pts with Cr<l.0 
(rag/alL). 
Reauns: The sample was 75% men, 16% >=75 years, and median Cr 1.2. Higher Cr pre- 
dicted worse outcomes: 24% of pts with Cr>=1.5 died, compared to 12% with Cr 1.1 to 
1.4 and 10% with Cr<=l.0. Associations between Cr and death were modified by both 
sex and age (p<0.001 for interactions), but effects were not additive. Highest risks were 
in women and elderly: For all-cause death, HR= 2.3 (95% confidence interval (CI) 
1.4,3.6) in women compared to HR=I.5 (1.1,2.1) in men; HR=I.8 (1.0,3.1) in pts >=75 
compared to HR=I.5 (1.1,2.1) in pts<75. For HF death, HR=5.9 (3.1,11.2) in women 
compared to HR=2.4 (1.5, 4.0) in men; HR=4.5 (1.6, 12.5) in pts>=75 compared to 
HR=2.4 (1.6,3,8) in pts<75. 
Conclusion: Cr >=1.5 strongly predicts mortality in HF outpatients, especially women 
and older pts. Use of Cr as an indicator of renal function in clinical settings and future 
studies should stratify for age and sex to avoid underestimating risks. 
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